Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Supporters say biomarker testing can tailor cancer and Alzheimer’s care; insurers and Medicaid urge limits and clinical utility review
Summary
Senate Bill 120 would require coverage of biomarker testing by insurers and Medicaid when a test is supported by medical and scientific evidence, a proposal proponents say would expand access to precision medicine for cancer and Alzheimer’s patients.
Senate Bill 120, introduced on behalf of Sen. Dan Innis, would require commercial health plans and Medicaid to cover biomarker testing when the test is supported by medical and scientific evidence. Proponents said biomarker testing guides precision medicine — especially in oncology and in diagnosis of Alzheimer's disease — and can help doctors avoid ineffective treatments and improve patient outcomes.
Grant Bossi, deputy chief of staff for the Senate, described the bill’s intent: “Biomarker testing is a tool we can use to improve treatment and outcomes, avoid unnecessary medical interventions and lower costs across New Hampshire's healthcare system.” Cancer…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
